Aging research spent twenty years trapped between bioethics panels treating cellular reset as transhumanist hubris and FDA categories that refused to recognize aging as a treatable indication. Yamanaka identified the four factors in 2006. Sinclair's lab restored vision in the mouse optic nerve via partial reprogramming in 2020. The intervening years filled with position papers from Kass, Fukuyama, every standing committee mistaking the rate of human deterioration for a moral floor.

Life Biosciences enrolled the first human patients in a Phase 1 partial reprogramming trial for NAION and glaucoma. Three Yamanaka factors only, Myc left out because Myc is the one that builds tumors. Endpoint is recovered vision in eyes the standard of care had already written off. Readout lands late this year, early next.

Each bioethics objection across two decades presupposed a sanctity it never grounded. Each FDA refusal to treat aging as an indication shifted the cost to whoever was already losing function. The first trial gets run anyway. The committees that tried to gate the question now get to read the data.